Vella Bioscience, the women’s wellness company developed by the team behind Viagra and Cialis, has launched Ebbtide – a vaginal insert designed to target the physiological source of menstrual cramping through uterine muscular relaxation, rather than masking symptoms systemically like oral pain medications.
The formulation uses Vella’s proprietary cannabidiol precision technology to deliver highly purified CBD isolate and CBDA directly to the tissue, combined with vitamin E. Preclinical and mechanistic studies validated the approach of reducing uterine contractility at the source. In clinical trials, 81% of women reduced or eliminated their use of oral medications while using Ebbtide.
“Ebbtide is different because it works at the physiological source of cramping and tension,” said Dr. Maria Uloko, board-certified urologist and member of Vella’s scientific advisory board. “The underlying science focuses on reducing uterine contractility through a novel combination of CBD and CBDA. That scientific rigor translates into real-world impact: meaningful options for women navigating menstrual discomfort, and more control over their daily lives.”
“Ebbtide brings our founding vision to life,” said co-founder and CEO Carolyn Wheeler. “It’s the belief that women deserve science built around them, at every stage of their lives. From menstruation to menopause, too much has been left unaddressed for too long.”
Beyond menstrual use, Vella positions Ebbtide for pelvic tension across perimenopause, menopause, and postpartum recovery.
